---
layout: default
title: Prednisone
description: "Prednisone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 140
evidence_level: L1
indication_count: 10
---

# Prednisone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Prednisoneï¼šå¾é¢¨æ¿•æ€§ç–¾ç—…åˆ°åœ“ç¦¿ç—‡

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Prednisone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Prednisone æ˜¯ä¸€ç¨®å»£æ³›ä½¿ç”¨çš„çš®è³ªé¡å›ºé†‡ï¼ŒåŸæœ¬ç”¨æ–¼é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ°£å–˜ã€ä¼‘å…‹ç­‰å¤šç¨®é©æ‡‰ç—‡ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**åœ“ç¦¿ç—‡ (Alopecia Areata)** æœ‰æ•ˆï¼Œç›®å‰æœ‰ **30+ å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ï¼ˆæ°£å–˜ã€ä¼‘å…‹ï¼‰ã€çš®è†šç–¾æ‚£ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopecia areataã€alopecia mucinosaã€telogen effluviumã€Quinquaud's folliculitis decalvansã€alopecia antibody deficiencyã€hereditary hypotrichosis with recurrent skin vesiclesã€alopecia-intellectual disability-hypergonadotropic hypogonadism syndromeã€atrichia with papular lesionsã€tenosynovitisã€granulomatous slack skin disease |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Go |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia areata</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Prednisone æ˜¯ä¸€ç¨®åˆæˆçš®è³ªé¡å›ºé†‡ï¼Œå…·æœ‰å¼·æ•ˆçš„æŠ—ç‚å’Œå…ç–«æŠ‘åˆ¶ä½œç”¨ã€‚å®ƒé€éæŠ‘åˆ¶å¤šç¨®ç‚ç—‡ä»‹è³ªå’Œå…ç–«ç´°èƒåŠŸèƒ½ä¾†ç™¼æ®ä½œç”¨ã€‚

åœ“ç¦¿ç—‡æ˜¯ä¸€ç¨®è‡ªé«”å…ç–«ç–¾ç—…ï¼Œç‰¹å¾µæ˜¯å…ç–«ç³»çµ±æ”»æ“Šæ¯›å›Šå°è‡´è„«é«®ã€‚é€™ç¨®ç–¾ç—…çš„ç—…ç†æ©Ÿè½‰æ¶‰åŠ T ç´°èƒä»‹å°çš„è‡ªé«”å…ç–«åæ‡‰ã€‚Prednisone çš„å…ç–«æŠ‘åˆ¶ä½œç”¨å¯ä»¥æŠ‘åˆ¶é€™ç¨®ç•°å¸¸çš„å…ç–«åæ‡‰ï¼Œå¾è€Œæ¸›å°‘å°æ¯›å›Šçš„æ”»æ“Šã€‚

è‡¨åºŠä¸Šï¼Œçš®è³ªé¡å›ºé†‡ï¼ˆåŒ…æ‹¬ prednisoneï¼‰å·²è¢«å»£æ³›ç”¨æ–¼æ²»ç™‚åš´é‡çš„åœ“ç¦¿ç—‡ï¼Œç‰¹åˆ¥æ˜¯èˆ‡ methotrexate ä½µç”¨æ™‚æ•ˆæœæ›´ä½³ã€‚æœ€æ–°çš„éš¨æ©Ÿå°ç…§è©¦é©—è­‰å¯¦äº†é€™ç¨®çµ„åˆç™‚æ³•çš„æœ‰æ•ˆæ€§ã€‚

### è‡¨åºŠè©¦é©—

| è©¦é©—ç·¨è™Ÿ | éšæ®µ | ç‹€æ…‹ | äººæ•¸ | ä¸»è¦ç™¼ç¾ |
|---------|------|------|------|---------|
| [NCT02037191](https://clinicaltrials.gov/study/NCT02037191) | Phase 3 | å·²å®Œæˆ | 90 | Methotrexate åŠ ä½åŠ‘é‡ prednisone vs å®‰æ…°åŠ‘æ²»ç™‚åš´é‡åœ“ç¦¿ |
| [NCT02953821](https://clinicaltrials.gov/study/NCT02953821) | Phase 4 | å·²å®Œæˆ | 172 | Acthar Gel ç”¨æ–¼ç³»çµ±æ€§ç´…æ–‘ç‹¼ç˜¡æ‚£è€… |
| [NCT03616964](https://clinicaltrials.gov/study/NCT03616964) | Phase 3 | å·²å®Œæˆ | 778 | Baricitinib ç”¨æ–¼ç³»çµ±æ€§ç´…æ–‘ç‹¼ç˜¡ |

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [36884234](https://pubmed.ncbi.nlm.nih.gov/36884234/) | 2023 | RCT | JAMA Dermatology | Methotrexate åŠ ä½åŠ‘é‡ prednisone å°åœ“ç¦¿å…¨ç¦¿/æ™®ç¦¿æœ‰æ•ˆ |
| [26735937](https://pubmed.ncbi.nlm.nih.gov/26735937/) | 2016 | Journal Article | Dermatology | Methotrexate èˆ‡ä¸­ä½åŠ‘é‡çš®è³ªé¡å›ºé†‡ä½µç”¨æ²»ç™‚åš´é‡åœ“ç¦¿çš„å®‰å…¨æ€§å’Œç™‚æ•ˆ |
| [37467740](https://pubmed.ncbi.nlm.nih.gov/37467740/) | 2023 | Case Series | Clin Exp Dermatol | Baricitinib èˆ‡ä½åŠ‘é‡çš®è³ªé¡å›ºé†‡ä½µç”¨æ²»ç™‚éå¸¸åš´é‡çš„åœ“ç¦¿æœ‰é¡¯è‘—æ”¹å–„ |
| [1444509](https://pubmed.ncbi.nlm.nih.gov/1444509/) | 1992 | Review | Arch Dermatol | åœ“ç¦¿æ²»ç™‚çš„ç™‚æ•ˆã€å®‰å…¨æ€§å’Œæ©Ÿè½‰å›é¡§ |
| [4571041](https://pubmed.ncbi.nlm.nih.gov/4571041/) | 1973 | Journal Article | Arch Dermatol | Prednisone æ²»ç™‚åœ“ç¦¿çš„å…ç–«å­¸ç ”ç©¶ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. alopecia mucinosa</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 10 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. telogen effluvium</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 1 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. Quinquaud's folliculitis decalvans</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 2 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. alopecia antibody deficiency</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL4ï¼ˆæœ‰æ–‡ç»æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**ç›¸é—œæ–‡ç»**ï¼šå…± 2 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. hereditary hypotrichosis with recurrent skin vesicles</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. atrichia with papular lesions</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.95%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. tenosynovitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.80%
- **è­‰æ“šç­‰ç´š**ï¼šL1ï¼ˆå¤šå€‹å¤§å‹ RCT æ”¯æŒï¼‰

### è‡¨åºŠè­‰æ“š

**è‡¨åºŠè©¦é©—**ï¼šå…± 4 é …

- è©¦é©—éšæ®µåˆ†å¸ƒï¼šPHASE1, PHASE2: 1é …, PHASE2: 1é …, PHASE3: 1é …, PHASE4: 1é …

**ç›¸é—œæ–‡ç»**ï¼šå…± 20 ç¯‡


</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. prolapse of lacrimal gland</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.66%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.66%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | ä¿ç™Œå¯§ç­‰ | éŒ åŠ‘/æ³¨å°„åŠ‘ | é¢¨æ¿•æ€§é—œç¯€ç‚ã€æ€¥æ€§ç—…ç—‡ã€çš®è†šç–¾æ‚£ç­‰ |

## å®‰å…¨æ€§è€ƒé‡

å®‰å…¨æ€§è³‡è¨Šè«‹åƒè€ƒåŸå» ä»¿å–®ã€‚

é•·æœŸä½¿ç”¨çš®è³ªé¡å›ºé†‡çš„å¸¸è¦‹æ³¨æ„äº‹é …ï¼š
- éª¨è³ªç–é¬†é¢¨éšª
- è¡€ç³–å‡é«˜
- å…ç–«æŠ‘åˆ¶å°è‡´æ„ŸæŸ“é¢¨éšªå¢åŠ 
- è…ä¸Šè…ºçš®è³ªåŠŸèƒ½æŠ‘åˆ¶

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**ç”˜è‰** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šç”˜è‰å»¶é•·çš®è³ªé¡å›ºé†‡ä½œç”¨
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡ç”˜è‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Latent Tuberculosis** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Fibrosis** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Psychotic Disorders** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç³–å°¿ç—…** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šé«˜è¡€ç³–ã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šç™²ç™‡ç™¼ä½œã€‚

**Water-Electrolyte Imbalance** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids may cause hypernatremia, hypokalemia, fluid retention, and elevation in blood pressure...

**Peptic Ulcer Perforation** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€æ„ŸæŸ“ã€‚

**Cushing Syndrome** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids mimic the effects of endogenous cortisol and aldosterone...

**Hyperlipidemias** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**ç”²ç‹€è…ºæ©Ÿèƒ½ä½ä¸‹** ğŸŸ¡ Moderate
- éœ€å¯†åˆ‡ç›£æ¸¬ã€‚å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¡ Moderate
- å¯èƒ½éœ€è¦èª¿æ•´åŠ‘é‡ã€‚

**Myocardial Infarction** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**é‡ç—‡è‚Œç„¡åŠ›** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**Muscular Diseases** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Keratitis, Herpetic** ğŸŸ¡ Moderate
- ä¸å»ºè­°ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

**Toxic Optic Neuropathy** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šProlonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma...

**éª¨è³ªç–é¬†ç—‡** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šCorticosteroids reduce osteoblastic function and inhibit the absorption of intestinal calcium, which can result in bone resorption and bone loss durin...

**æ¶ˆåŒ–æ€§æ½°ç˜** ğŸŸ¡ Moderate
- æ‡‰é¿å…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šå‡ºè¡€ã€‚

**Scleroderma, Localized** ğŸŸ¡ Moderate
- æ³¨æ„äº‹é …ï¼šIn patients with scleroderma, corticosteroids may precipitate renal crisis with malignant hypertension, possibly via steroid-induced increases in reni...

**Strongyloidiasis** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Thromboembolism** ğŸŸ¡ Moderate
- é¢¨éšªåŒ…æ‹¬ï¼šè¡€æ “ã€‚

**Infections** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚é¢¨éšªåŒ…æ‹¬ï¼šæ„ŸæŸ“ã€‚å¯èƒ½å±åŠç”Ÿå‘½ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šGo**

**ç†ç”±ï¼š**
æœ‰é«˜å“è³ªçš„éš¨æ©Ÿå°ç…§è©¦é©—ï¼ˆåŒ…æ‹¬ 2023 å¹´ç™¼è¡¨æ–¼ JAMA Dermatology çš„ç ”ç©¶ï¼‰è­‰å¯¦ prednisone èˆ‡ methotrexate ä½µç”¨å°åš´é‡åœ“ç¦¿æœ‰æ•ˆã€‚é€™å€‹é æ¸¬æœ‰å……åˆ†çš„è‡¨åºŠè­‰æ“šæ”¯æŒã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ ¹æ“šæ‚£è€…å€‹åˆ¥æƒ…æ³è©•ä¼°é¢¨éšªæ•ˆç›Š
- è€ƒæ…®èˆ‡ methotrexate æˆ– JAK æŠ‘åˆ¶åŠ‘ä½µç”¨
- åˆ¶å®šé•·æœŸç›£æ¸¬è¨ˆç•«ï¼ˆéª¨å¯†åº¦ã€è¡€ç³–ç­‰ï¼‰

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Vonoprazan]({{ "/drugs/vonoprazan/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Regorafenib]({{ "/drugs/regorafenib/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/prednisone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_prednisone,
  title = {Prednisoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/prednisone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
